Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2016 Q1- Text added to 2016 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
acid, adrenoleukodystrophy, adult, AMD, analog, antagonist, antiepileptic, ASCO, broadened, burden, carcinoma, care, chain, chemotherapy, China, colorectal, deficit, dosed, ethnicity, fall, fluorouracil, ganaxalone, gender, Germany, head, hepatocellular, holder, hospital, Humira, ICU, illustrated, immunotherapy, incremental, investigational, Japan, Kingdom, lengthy, Leucovorin, leveraging, licensee, listed, Liver, locally, lt, lung, match, metastatic, molecular, monotherapy, morbidity, neck, noncash, nongenetic, Notice, NSCLC, nucleotide, Nucorion, ONIVYDE, Ono, Orange, pevonedistat, Prodrug, proportional, RAS, ratio, reversal, seribantumab, signature, solid, Spain, stage, threshold, Track, transition, unenforceable, vehicle, Wuxi
Valuein 2016 Q1 filing- Value in 2016 Q2 filing
Original filings
Filing view